Key facts
- It has raised $39.7M; the latest was Later Stage VC ($39.7M) in Mar 2025.
- Notable investors include Novo Holdings, Innovestor, Industrifonden, Investinor, HealthCap — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Tribune Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tribune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tribune Therapeutics
Operator of a preclinical biopharmaceutical company intended to treat fibrosis regardless of the cause, tissue, or diagnosis. The company specializes in developing novel medicines that target the family of extracellular matrix-associated proteins central to the development of fibrosis to stop this cycle of scar formation that leads replacement of healthy, functional tissue with collagen and other connective material, enabling medical professionals to treat patients with fibrotic diseases.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2020
- Employees
- 10
- Website
- tribunetx.com/
- Ownership
- Privately Held (backing)
Tribune Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tribune Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tribune Therapeutics in its N-PORT filings yet. We sweep new filings monthly.